RXRX

Conviction 4HealthcareScan · Mon, Aug 10, 2026

Bullish engulfing

RXRX$3.29+2.02%

ResistanceSupportVol 14Insider sell

Vol MA14 16.82M

May 11May 28Jun 16Jul 6Jul 23Aug 10

RECURSION PHARMACEUTICALS, INC.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.recursion.com ↗

Price3.29

Change+2.02%

Gap-0.47%

Rel volume0.90×

Avg volume18.79M

Avg $ vol58.17M

SMA 203.10

SMA 503.31

SMA 2003.82

Price vs 50-0.82%

Price vs 200-13.92%

MA stackbearish

50/200 cross—

Supertrenddown · 3.54

RSI (14)53

MACD hist0.03

MACD crossbull · 4d

Stoch %K / %D85 / 74

ADX (14)12

+DI / −DI26 / 22

RSI divergence—

MACD divergence—

ATR %+5.68%

ADR %4.98%

52w high6.79

52w low2.84

From 52w high-51.62%

Above 52w low+15.67%

New 52w highNo

SqueezeOff

Bollinger width17.57%

%B0.84

Donchian pos74.17%

Donchian high3.44

Donchian low2.84

AVWAP (52w high)4.10

vs AVWAP high-19.97%

AVWAP (52w low)3.34

vs AVWAP low-1.63%

OBV trendFlat

Chaikin MF (20)-0.02

Today vs 20d0.90×

Avg vol (14d)16.82M

Avg vol (20d)18.79M

Avg $ vol (20d)58.17M

Market cap1.76B

RS 3m (vs SPY)-7.23%

RS 6m (vs SPY)-23.66%

RS line new highNo

Trend template0/8

Technical rank27.0

1 week+3.30%

1 month-7.72%

3 months-1.05%

6 months-17.46%

1 year-39.28%

YTD-21.79%

P/E-2.73

P/B1.92

P/S23.55

P/FCF-4.65

EPS-1.44

Div yield—

ROE-70.47%

ROA-53.17%

Debt/Eq0.00

Current5.03

EV/EBITDA-2.15

Gross margin—

Net margin-863.35%

Rev growth26.92%

EPS growth-39.06%

Price target6.50

Target upside97.87%

Analyst ratingHold

Institutional77.40%

Ent. value1.21B

Revenue7.67M

Net income-131M

Gross profit—

Free cash flow-378.28M

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out524.68M

Employees600

ListedFri, Apr 16, 2021

Free float409.84M

Float %78.5%

Short interest180.76M

Days to cover6.7d

Short volume30.7%

Squeeze score65 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.25 vs −$0.23

Last surprise-8.7% miss

Setup gradeD

Conviction4 / 100

Pattern quality—

Tech rank27.0 / 100

Group rank86 / 100 · Leading

Status lane—

Setup direction—

Pattern family

Resistance—

Support—

Days since event—

Candle confirmBullish engulfing

News sentiment—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in RXRX

All disclosures →

No recent disclosed trades by Congress in RXRX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in RXRX · 7 buys · 3 sells

Insider	Side	Shares	Value	Traded	Filed
Borgeson Blake Director · Class A Common Stock · 2026-08-04	Sell	30K	$98K	2026-08-04	2026-08-06
Borgeson Blake Director · Class A Common Stock · 2026-07-07	Sell	40K	$159K	2026-07-07	2026-07-09
Bumpus Namandje Director · Class A Common Stock · 2026-06-18	Sell	3.96K	$13K	2026-06-18	2026-06-22
Bumpus Namandje Director · Class A Common Stock · 2026-06-17	Grant	88.42K	—	2026-06-17	2026-06-22
Borgeson Blake Director · Class A Common Stock · 2026-06-17	Grant	88.42K	—	2026-06-17	2026-06-22
HERSHBERG ROBERT Director · Class A Common Stock · 2026-06-17	Grant	88.42K	—	2026-06-17	2026-06-22
Michor Franziska Director · Class A Common Stock · 2026-06-17	Grant	88.42K	—	2026-06-17	2026-06-22
Dar Zavain Director · Class A Common Stock · 2026-06-17	Grant	88.42K	—	2026-06-17	2026-06-22
Sun Elaine D Director · Class A Common Stock · 2026-06-17	Grant	88.42K	—	2026-06-17	2026-06-22
Li Dean Y Director · Class A Common Stock · 2026-06-17	Grant	88.42K	—	2026-06-17	2026-06-22

SEC filings

EDGAR filings in RXRX · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.